Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: 9 | History Defined

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

Benzinga

Thiruvananthapuram to host global oncology conclave from Saturday

Thiruvananthapuram

The Hindu

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder (MDD). Relmada shares traded in a range of $26.02 to $27.96 on a day volume of 173.79 thousand shares, closed regular trading…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

'Great relief': ACT govt signals intention to gynaecology oncology unit

Canberra Health Services has advertised for a gynaecological oncologist.

The Canberra Times

Physician heal thyself? After 4 years of treatment for stage 4 cancer I just wanted some encouraging words from my oncologist

My oncologist has one of those little motivational prints hanging on his waiting room wall, with the simple statement, “Trust Your Instincts”. One day, bored with the long purgatory of the waiting room, I tweet this news to the world with the observation: “If I trusted my instincts, I’d run…

The Conversation

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Benzinga

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket

Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00 per share.

Benzinga

July 30 — Remembering the Founder of the Cancer Institute (WIA), Dr. Muthulakshmi Reddy

Dr. Muthulakshmi Reddy made several appeals to set up a specialized cancer centre in the city of Madras.

The Hindu

Coimbatore oncologist launches a digital flip book to create tobacco awareness

A 15-page digital flip book launched as a part of an ongoing monthly campaign urges people to quit tobacco for their own health and the health of the environment

The Hindu

Cancer consultations to change in North East due to workforce shortages

Lung, breast, and colorectal cancer patients across the North East will have their consultations in specific hospitals to maintain "equitable access" to treatment

Chronicle Live

3 Winning Healthcare Stocks to Buy for the Rest of the Summer

Increased health awareness and the rapidly aging population are expected to drive the growth of healthcare companies. Healthcare stocks Cigna Corp. (CI), Humana (HUM), and McKesson Corp. (MCK) have bucked the market downtrend and are in momentum. Since the market is expected to remain under pressure in the near term,…

StockNews.com

ALX Oncology Shares Soar As FDA Grants Orphan Drug Status To Blood Cancer Candidate

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALX Oncology Holdings’ (NASDAQ: ALXO) Evorpacept for the treatment of patients with acute myeloid leukemia (AML).

Benzinga

Glasgow Beatson cancer nurse fighting the disease given terminal diagnosis

Sarah McCann is a lead advanced nurse practitioner for active oncology at Glasgow's Beatson West of Scotland Cancer Centre, dedicating her life to treating cancer patients.

Glasgow Live

Get all your
news in one place.

100's of premium titles.
One news app.

Daily Mirror

Emmerdale's Faith Dingle to die as she discovers cancer is terminal

Much-loved matriarch Faith Dingle, played by Sally Dexter, will attend an oncology appointment after having her scan - but it's not good news on Emmerdale

Benzinga

F-star Therapeutics Shares Are Rallying Today - Read Why

invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ:FSTX) for $7.12 per share. The proposed acquisition values F-star at approximately $161 million. Just a year ago, F-star priced its IPO at $7. F-star's next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharma's existing capabilities and reinforces its global…

Benzinga

Ikena Oncology Secures Fast Track designation From FDA For Pleural Cancer Candidate

Ikena Oncology, Inc. (NASDAQ: IKNA) received Fast Track designation from the U.S. Food and Drug Administration (FDA) for IK-930, in patients with unresectable NF2-deficient malignant pleural mesothelioma (MPM).

Benzinga

Ikena Oncology's Return On Capital Employed Insights

Ikena Oncology (NASDAQ:IKNA) brought in sales totaling $3.38 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 702.04%, resulting in a loss of $16.84 million.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Cancer Program

LAVA Therapeutics N.V. (NASDAQ:LVTX) hosted a clinical update call focused on initial Phase 1/2a data for LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the American Society of Clinical Oncology and European Hematology Association meetings. "Although preliminary, these data support our view of LAVA-051 as a promising candidate…

The Canberra Times

Time is running out for permanent cancer surgery unit in Canberra

A group of doctors have been lobbying both the territory and federal government for funding for a permanent surgery unit.

Benzinga

Kymera Therapeutics Commences Initial-Stage Oncology Trials

Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413.

Benzinga

Clovis Shares Jumps After Highlighting Data From Targeted Radiotherapy Trial

Clovis Oncology Inc (NASDAQ:CLVS) announced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286). Overall, in nine patients treated in the first two dose cohorts, 177Lu-FAP-2286 demonstrated a manageable safety profile and encouraging evidence of activity, including a confirmed RECIST partial response in…

Benzinga

MorphoSys Stock Skyrockets On Entering Equity Participation and License Agreements With HIBio

MorphoSys AG (NASDAQ:MOR) and Human Immunology Biosciences, Inc. (HIBio), a biotechnology company, have established an equity participation agreement and license agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody. HIBio is a biotechnology company based in South San Francisco that focuses on discovering and…

Belfast Live

Belfast Pops Orchestra take on the Ulster Hall for children's cancer charity

Leader Stephen Cullen was inspired by his experience at the Children’s Haematology and Oncology Unit at the Royal

Benzinga

AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial

AbbVie Inc (NYSE:ABBV) announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 phase 2 trial of epcoritamab. Epcoritamab demonstrated efficacy with durable responses in patients who had previously received at least two prior lines of anti-lymphoma therapy. The study cohort, which included 157 relapsed/refractory LBCL patients, demonstrated…

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Canberra Health Services

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.